Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open Label Study of Single Dose Rhenium Re 188 P2045 in Patients With Lung Cancer Who Have Received or Refused to Receive Prior Chemotherapy

NCT00100256 is registered in ClinicalTrials.gov with Andarix Pharmaceuticals as lead sponsor.

NCT NCT00100256
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00100256 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open Label Study of Single Dose Rhenium Re 188 P2045 in Patients With Lung Cancer Who Have Received or Refused to Receive Prior Chemotherapy
Lead sponsor
Andarix Pharmaceuticals
Phase
Phase 1/2
Overall status
Unknown status
Start date
January 31, 2004
Completion date
April 20, 2025
Enrollment
60 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

carcinoma, non-small-cell lung, carcinoma, small cell, lung neoplasms, neoplasm recurrence, local